Summit Therapeutics Inc
SMMT24.120USD
+0.500+2.12%
收盤 04/30, 16:00（美東）報價延遲15分鐘
17.79B總市值
虧損本益比TTM
關於 Summit Therapeutics Inc 公司
Summit Therapeutics Inc. 是一家專注於發現、開發和商業化患者、醫生和護理人員藥物療法的生物製藥公司。該公司的開發候選藥物是 ivonescimab，這是一種潛在的同類首創雙特異性抗體，旨在將通過阻斷 PD-1 產生的免疫療法效果與抗 VEGF 化合物的抗血管生成效果結合到單個分子中。該公司開發了用於非小細胞肺癌 (NSCLC) 的 ivonescimab，具體啓動了以下適應症的 III 期臨牀試驗，例如 ivonescimab 聯合化療用於表皮生長因子受體 (EGFR) 突變、局部晚期或轉移性非鱗狀 NSCLC 患者，這些患者在接受第三代 EGFR 酪氨酸激酶抑制劑 (HARMONi) 治療後病情出現進展，以及 ivonescimab 聯合化療用於一線轉移性鱗狀 NSCLC 患者 (HARMONi-3)。其 ivonescimab 採用 Akeso 的 Tetrabody 技術設計。
公司簡介
公司代碼SMMT
公司名稱Summit Therapeutics Inc
上市日期Oct 14, 2004
成立日期2020
CEODr. Mahkam (Maky) Zanganeh
員工數量159
證券類型Ordinary Share
年結日Oct 14
公司地址601 Brickell Key Drive
城市MIAMI
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編33131
電話13052032034
網址https://www.smmttx.com/
公司代碼SMMT
上市日期Oct 14, 2004
成立日期2020
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
555.68M
+0.72%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.38M
+0.24%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Jeff Huber
Mr. Jeff Huber
Director
Director
--
--
Mr. Kenneth A. Clark, J.D.
Mr. Kenneth A. Clark, J.D.
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Robert F. Booth, Ph.D.
Dr. Robert F. Booth, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mostafa Ronaghi, Ph.D.
Dr. Mostafa Ronaghi, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
555.68M
+0.72%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.38M
+0.24%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Jeff Huber
Mr. Jeff Huber
Director
Director
--
--
收入明細
單位: USD更新時間: 4月6日 週日
單位: USD更新時間: 4月6日 週日
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
暫無數據
地區USD
名稱
營收
佔比
Latin America
0.00
0.00%
業務
地區
暫無數據
股東統計
更新時間: 2月21日 週五
更新時間: 2月21日 週五
持股股東
股東類型
持股股東
股東統計
佔比
Duggan (Robert William)
75.35%
Zanganeh (Mahkam)
4.80%
Xia (Yu)
4.27%
Baker Bros. Advisors LP
3.31%
The Vanguard Group, Inc.
1.58%
Other
10.68%
持股股東
股東統計
佔比
Duggan (Robert William)
75.35%
Zanganeh (Mahkam)
4.80%
Xia (Yu)
4.27%
Baker Bros. Advisors LP
3.31%
The Vanguard Group, Inc.
1.58%
Other
10.68%
股東類型
股東統計
佔比
Individual Investor
84.90%
Investment Advisor
4.57%
Hedge Fund
4.06%
Investment Advisor/Hedge Fund
3.86%
Research Firm
0.40%
Pension Fund
0.02%
Bank and Trust
0.02%
Sovereign Wealth Fund
0.01%
Other
2.16%
機構持股
更新時間: 1月20日 週一
更新時間: 1月20日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
403
717.89M
97.58%
+5.51M
2024Q4
388
717.73M
97.33%
+5.42M
2024Q3
325
708.90M
96.17%
+11.45M
2024Q2
260
692.13M
98.13%
+14.08M
2024Q1
228
669.32M
95.38%
+36.91M
2023Q4
210
620.08M
88.82%
-5.65M
2023Q3
205
616.45M
88.38%
+11.96M
2023Q2
199
619.05M
88.77%
+407.10M
2023Q1
178
604.96M
86.79%
+406.66M
2022Q4
154
191.34M
95.05%
+13.11M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Duggan (Robert William)
551.70M
74.81%
+3.33M
+0.61%
Sep 13, 2024
Zanganeh (Mahkam)
35.38M
4.8%
+84.32K
+0.24%
Apr 17, 2024
Xia (Yu)
31.52M
4.27%
--
--
Apr 17, 2024
Baker Bros. Advisors LP
24.42M
3.31%
--
--
Dec 31, 2024
The Vanguard Group, Inc.
11.67M
1.58%
+724.04K
+6.61%
Dec 31, 2024
Fidelity Management & Research Company LLC
8.02M
1.09%
-277.94K
-3.35%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
7.55M
1.02%
+402.22K
+5.63%
Dec 31, 2024
T. Rowe Price Associates, Inc.
6.47M
0.88%
+1.11M
+20.72%
Dec 31, 2024
State Street Global Advisors (US)
5.60M
0.76%
+2.13M
+61.54%
Dec 31, 2024
Geode Capital Management, L.L.C.
3.20M
0.43%
+101.04K
+3.26%
Dec 31, 2024
查看更多
持股ETF
更新時間: 4月6日 週日
更新時間: 4月6日 週日
機構名稱
佔比
Tema Oncology ETF
2.77%
Invesco Nasdaq Biotechnology ETF
1.46%
ProShares Ultra Nasdaq Biotechnology
1.42%
Range Cancer Immunotherapy ETF
1.24%
Virtus LifeSci Biotech Clinical Trials ETF
1.04%
SPDR S&P Biotech ETF
0.92%
Invesco NASDAQ Next Gen 100 ETF
0.89%
Invesco ESG NASDAQ Next Gen 100 ETF
0.67%
Direxion Daily S&P Biotech Bull 3X Shares
0.58%
Simplify Next Intangible Core Index ETF
0.35%
查看更多
Tema Oncology ETF
佔比2.77%
Invesco Nasdaq Biotechnology ETF
佔比1.46%
ProShares Ultra Nasdaq Biotechnology
佔比1.42%
Range Cancer Immunotherapy ETF
佔比1.24%
Virtus LifeSci Biotech Clinical Trials ETF
佔比1.04%
SPDR S&P Biotech ETF
佔比0.92%
Invesco NASDAQ Next Gen 100 ETF
佔比0.89%
Invesco ESG NASDAQ Next Gen 100 ETF
佔比0.67%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.58%
Simplify Next Intangible Core Index ETF
佔比0.35%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據